| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
South African Business |
|
|
DESCRIPTION OF BUSINESS |
|
|
OPERATIONAL HIGHLIGHTS |
|
|
GROUP REVENUE* |
|
|
LEADING BRANDS |
|
|
NUMBER OF EMPLOYEES# |
|
|
PRODUCT TYPES |
| |
|
|
|
|
|
|
|
|
|
Revenue: R4,9 billion (+30%) |
|
|
|
|
|
|
|
|
|
| |
Sales, marketing and
distribution |
|
|
Provides a basket of quality, affordable
branded, generic, OTC, self-medication, infant
nutritional and personal care products to
pharmacies, retail pharmacy chains, hospitals,
clinics, prescribing specialists, dispensing general
practitioners, managed healthcare funders
and retail stores across the private and public
sectors as well as to selected export markets.
Active Pharmaceutical Ingredients ("APIs") are
sold into South Africa and export territories. |
|
|
- Aspen remains the leading supplier of
medicines to the South African private and
public sectors, representing 34% of generic
product sales and 13% of total pharmaceutical
sales in the private sector. Growth of 20%
was recorded in the private sector, 5% ahead
of total market growth. Aspen's OTC division
grew 8% ahead of the market at 21%. One in
five script lines dispensed by a pharmacist in
South Africa is for an Aspen product.
|
|
|
 |
|
|
Altosec, CiLift, Flusin,
Infacare, Lamzid,
Lenadol, Lennon
Dutch Medicines,
Mybulen, Pharmapress,
Sinuclear, Vectoryl and
Woodwards Gripe
Water |
|
|
543 |
|
|
 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Manufacturing operations |
|
|
Aspen is Africa’s largest manufacturer of generic
pharmaceuticals and one of the world’s top
20 generic manufacturers. Significant
investments have been made in the expansion,
diversification and upgrade of manufacturing
capability and capacity to supply quality,
affordable products for the Group’s growing
local and international markets. Aspen also has
infant nutritional and API manufacturing facilities.
|
|
|
- Manufacturing capability has been diversified
into the manufacture of steriles with the
commencement in August 2009 of the export
of eye drops to the United States for Prestige
Brands Inc. Capital expenditure projects to
unlock manufacturing and packing capacity
and to enhance manufacturing processes are
substantially complete.
|
|
|
|
|
|
|
|
|
3 104 |
|
|
 |
| |
International Business |
|
|
DESCRIPTION OF BUSINESS |
|
|
OPERATIONAL HIGHLIGHTS |
|
|
GROUP REVENUE* |
|
|
LEADING BRANDS |
|
|
NUMBER OF EMPLOYEES# |
|
|
PRODUCT TYPES |
| |
|
|
|
|
|
|
|
|
|
Revenue: R3,6 billion (+245%) |
|
|
|
|
|
|
|
|
|
| |
Global brands |
|
|
Aspen’s international distribution platform
has been developed to facilitate supply of
global brands into numerous worldwide
markets. Aspen Global manages the
intellectual property rights, regulatory and
commercialisation strategy of this portfolio
of specialist, branded products. |
|
|
- The portfolio of global brands has been
extended to seven recognised brands which
provide a springboard for Aspen into new
international markets. Transition to Aspen's
distribution network is scheduled to be materially
complete by the end of the 2010 financial year.
|
|
|
 |
|
|
Aggrastat, Aldomet,
Eltroxin, Imuran,
Indocid, Lanoxin and
Zyloric |
|
|
31 |
|
|
 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Asia Pacific |
|
|
Distributes niche, branded pharmaceutical
and consumer products in Australia and
New Zealand and has recently extended
its distribution in South East Asia. |
|
|
- Despite Australia's 25% legislated price cut in
August 2008, Aspen Australia delivered strong
growth for the sixth consecutive year since inception.
Contributors to growth included implementation of
innovative marketing and pricing strategies and the
negotiation of licensing arrangements for additional
differentiated products. 5,3% of all scripts written in
Australia prescribe an Aspen brand.
|
|
|
 |
|
|
Bio Oil, Cardizem,
Di-gesic, Neotigaston,
Keflex, Murine, Proscar,
Spray Fresh, Transderm
Nitro and Tritace |
|
|
73 |
|
|
 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Sub-Saharan Africa |
|
|
Aspen’s 60% subsidiary, Shelys, has operations
in Tanzania, Kenya and Uganda. Shelys has a
portfolio of well recognised pharmaceutical
and OTC brands which are promoted through
an established distribution platform in the
region. This forms the foundation for Aspen’s
presence in sub-Saharan Africa. |
|
|
- Growth was recorded despite political unrest in
Kenya and negative currency fluctuations. Shelys
received the President of Tanzania's award for
the Best overall Manufacturer of the Year across
all industries.
|
|
|
 |
|
|
Action, Coldril,
Diclopar, Good
Morning Lung Tonic,
Hemovit, Koflyn,
Malafin, Mara Moja,
Mucolyn and Sulphador |
|
|
877 |
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Latin America |
|
|
Aspen’s Latin American operations in Brazil,
Mexico and Venezuela have historically supplied
generic pharmaceuticals to the hospitals
and public sector. Focused attention is being
given to unlocking growth opportunities for
branded pharmaceutical and OTC products in
the private sectors across Latin America. The
Group has manufacturing facilities in Brazil and
Mexico. |
|
|
- Full control of the Latin American businesses will
be attained in the year ahead. Focus has been
shifted to the development of the private market
for branded products. A sales representative force
has been established and a portfolio of branded
pharmaceutical and OTC products has been
acquired in Brazil. Commercial production of
penem and penicillin injectables commenced
at the completed Brazilian facilities.
|
|
|
 |
|
|
Ceflen, Cellexina, Enjoy,
Heptron, Hidrosone,
Omeprazole,
Pravastatina, Sulidaco,
Tazpen and Zylpen |
|
|
645 |
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Oncology joint venture |
|
|
Aspen’s 50% joint venture develops and
manufactures a portfolio of oncology products
with intended supply to international markets.
The manufacture and development facilities
are situated in Bangalore, India. |
|
|
- Manufacture and supply arrangements were
concluded with two leading multinational
pharmaceutical companies. The facility obtained
Australian Therapeutic Goods Association ("TGA")
approval and 14 products are anticipated to be
filed with the US Food and Drug Administration
("FDA") by December 2009.
|
|
|
 = percentage of revenue segment
|
|
|
Anticipated to be
commercialised in
2011 |
|
|
89 |
|
|
 |
| |
|
|
|
|
|
|
|
|
|
* Amounts stated are from
continuing operations.
# Full-time and part-time employees. |
|
|
|
|
|
|
|
|
|
